Ovid Therapeutics Inc.
NASDAQ:OVIDBiotechnology
-$0.11 today
- Market cap
- $426.53M
- Beta
- 0.18
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.33
Volume 2.16M
Average 3.07M
OVID Common Stock Issued
Cash raised by issuing new shares.
Ovid Therapeutics Inc.NASDAQ: OVID
Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026
Common stock issued growth accelerates
Q1 FY2026 common stock issued of $88.98M rose 684376.9% year over year, ahead of the +40238.1% change in trailing-twelve-month common stock issued. Sequentially, it rose 18.4% from the prior quarter. Over 3 fiscal years it compounded at +646.7% a year.
Context
- Common stock issued amounted to 1037.1% of revenue in FY2025, up 927.2 pp from a year earlier.
- Common stock issued increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +684376.9% holds above the trailing-twelve-month pace of +40238.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 75.21M USD
- Year-over-year change
- +11991.2%
- 4-year CAGR
- +200.2%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 75.21M | +11991.2% |
| FY2024 | 2024-12-31 | 622K | +16.2% |
| FY2023 | 2023-12-31 | 535.2K | +196.3% |
| FY2022 | 2022-12-31 | 180.66K | -80.5% |
| FY2021 | 2021-12-31 | 925.4K | — |
Common Stock Issued vs competitors
How OVID compares with its peers on the latest reported figures
- OVID's LTM Mar 2026 common stock issued of $164.18M is the 5th largest of the 11 companies compared; the peer median is $58.29M.
- Its year-over-year change of +40238.1% is the 2nd highest of 11, against a peer median of +29.9%.
- Common stock issued amounts to 2305.2% of revenue for OVID, versus a peer median of 132.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $486.47M | +117.8% | +110.5% | 677.6% | |
| LTM Jun 2026 | $266.89M | +19.9% | +70.9% | 4865.7% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $226.61M | +3793.8% | +768.3% | — |
| LTM Mar 2026 | $180.34M | +39.9% | +29.0% | 562.2% | |
| LTM Mar 2026 | $164.18M | +40238.1% | +646.7% | 2305.2% | |
| LTM Mar 2026 | $85.84M | +73270.1% | — | 12.8% | |
| LTM Mar 2026 | $30.73M | -83.5% | +646.6% | — | |
| LTM Mar 2026 | $24.86M | -60.1% | -15.0% | 31.2% | |
| LTM Mar 2026 | $19.28M | -77.6% | -17.8% | 132.6% | |
| LTM Mar 2026 | $4.07M | +506.9% | -9.7% | 11.1% | |
| LTM Mar 2026 | $215K | -99.9% | — | — | |
| Peer median (excluding OVID) | $58.29M | +29.9% | +50.0% | 132.6% | |
Competitors are the stored peer set for OVID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 119.84M | (54.17M) | (52.34M) | (26.43M) | (17.41M) |
| Depreciation & Amortization | 237K | 1.38M | 1.6M | 613K | 273K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 6.56M | 7.29M | 6.28M | 4.81M |
| Change in Working Capital | (16.81M) | (8.23M) | 2.39M | (150K) | (4.1M) |
| Accounts Receivables | 141.76K | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.7M | (5.17M) | 1.75M | (512K) | (1.23M) |
| Other Working Capital | (18.66M) | (3.06M) | 635.51K | 362K | (2.87M) |
| Other Non-Cash Items | 15.35M | (764.94K) | (4.71M) | (36.26M) | (21.9M) |
| Operating Cash Flow | 118.61M | (55.23M) | (45.78M) | (55.96M) | (38.33M) |
| Capital Expenditures | (189.41K) | (1.42M) | (137.46K) | (71K) | 0 |
| Acquisitions (Net) | (1.63M) | (2.5M) | (10M) | 0 | 0 |
| Purchases of Investments | (1.63M) | (172.96M) | (112.44M) | (73.25M) | (91.85M) |
| Sales of Investments | 0 | 90M | 120M | 128M | 42M |
| Other Investing Activities | (5.4K) | (1M) | (97.15K) | (89K) | 0 |
| Investing Cash Flow | (1.82M) | (87.88M) | (2.58M) | 54.59M | (49.85M) |
| Debt Repayment | 0 | 0 | 30M | 0 | 0 |
| Common Stock Issued | 925.4K | 180.66K | 535.2K | 622K | 75.21M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (21.31K) | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 904.08K | 180.66K | 30.54M | 622K | 75.21M |
| Effect of Forex Changes | (1.93M) | 0 | 0 | 0 | (167K) |
| Net Change in Cash | 115.76M | (142.93M) | (17.83M) | (740K) | (13.15M) |
| Free Cash Flow | 118.42M | (56.65M) | (45.92M) | (56.03M) | (38.33M) |
Ovid Therapeutics Inc.
NASDAQ:OVID
Intrinsic Alpha fair value
Locked
Current Price
$2.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.